Breast Care A-Z · Concept · BCSCREEN

Breast cancer screening

also: breast screening, mammography screening, NHS Breast Screening Programme, breast screening programme UK

Breast cancer screening is the use of regular mammograms to look for breast cancer before it causes any symptoms, so it can be found and treated early. You may be wondering when to start, whether to pay privately before your NHS invitation arrives, or whether family history changes when screening should begin.

Quick answers

At what age does NHS breast cancer screening start?

The NHS Breast Screening Programme invites women from age 50 to 71, with the first invitation arriving between the 50th and 53rd birthday. Some areas are extending to age 47 as part of an ongoing programme expansion.

Should I have a private mammogram before age 50?

For women at average risk, the evidence for screening before 50 is weaker than from 50 onwards. For women with significant family history, an earlier and more intensive pathway is usually appropriate — but that should be set up through a familial-risk clinic, not by ad hoc private mammograms. Private mammography from 40 for women with concerns or a less-strong family history is reasonable as an adjunct, with realistic expectations of the benefit.

How often should I have a mammogram?

NHS programme: every 3 years from 50. Private (average risk): often offered annually, though every 2 years is also reasonable. High-risk pathway: annual, sometimes with additional MRI.

PUBLIC HEALTH · PREVENTION breast cancer screening NHS Breast Screening Programme · NHSBSP population-level mammographic surveillance to detect cancer before symptoms arise PLATE XXXIV FIG 01 Mammography setup diagram X-RAY SOURCE compression paddle detector plate image acquisition CC view craniocaudal MLO view mediolateral oblique i X-ray source (tungsten anode) ii Compression paddle (reduces dose) iii Breast tissue (compressed) iv Detector plate (digital flat panel) v Image acquisition (PACS/RIS) Mean glandular dose: ~1.5 mGy per view · Standard protocol: 2 views per breast (CC + MLO) · Total: ~6 mGy Equivalent background radiation: ~3 months · Risk of radiation-induced cancer: negligible at screening doses Images reported by 2 independent radiologists; arbitration if discordant (double reading standard in NHSBSP) Digital mammography now standard; tomosynthesis (3D) increasingly available at assessment centres Contrast-enhanced mammography emerging for high-risk or equivocal cases; MRI for BRCA carriers PANEL B — WHO IS INVITED? Age range: 50–70 yrs (routine) (rollout to 50–71 underway; AgeX trial complete) Frequency: every 3 years Eligibility: registered with GP · Invitation sent automatically via NHSBSP · Can self-refer if missed or outside age · Transgender women may be invited PANEL C — RECALL OUTCOMES Normal → routine 3-yr recall Recall (~5%) → assessment clinic → further imaging ± biopsy Cancer detected → MDT → Tx ~1 in 100 recalled → cancer confirmed ~1 in 25 screened → further assessment Results by letter within 2 weeks FIG 02 Routinely invited vs Requires referral / discussion Routinely invited Referral / discussion Age 50–71 (rollout); 47–73 AgeX trial Under 50 or over 70 Symptoms GP registered, no symptoms Symptomatic — urgent referral Implants No current breast concerns Implants — specialist centre Risk Average population risk BRCA1/2 — annual MRI Pregnancy Previous normal screen Pregnancy — defer screening Breastfeeding 3-year recall interval Breastfeeding — defer Dense breasts Standard mammogram Dense breasts — supplemental USS Breast concern Two standard views (CC+MLO) Current concern — refer urgent Prior Ca Digital mammography Prior breast cancer — specialist Genetic Centralised recall system Genetic syndrome carrier — MDT FIG 03 Benefits vs Harms of screening Aspect Benefit Potential harm Cancer detection Earlier stage at diagnosis Overdiagnosis (~20%) Mortality ~20% relative reduction False reassurance False positive — Anxiety, unnecessary biopsy Sensitivity ~84% screen-detected 16% false negatives Recall rate 5% recalled for assessment Anxiety + further tests Lead time Earlier detection window Lead-time bias Treatment Less radical intervention Overtreatment of DCIS Radiation Low dose (0.1 mSv) Trivial theoretical risk Cost-effectiveness ~£3,000 per QALY gained Resource intensive FIG 04 Screening pipeline STEP 1 Invitation letter sent › STEP 2 Attend appt mobile unit › STEP 3 Mammogram 2 views each › STEP 4 Radiology double-read › STEP 5 Result letter 2 weeks › STEP 6 Recall if needed Recall: ~5% of screened women recalled for assessment; ~1% of recalled women have cancer confirmed. Assessment clinic: additional mammographic views, ultrasound, stereotactic or USS-guided core biopsy. Triple assessment: clinical examination + imaging + biopsy — sensitivity approaches 99% in specialist centre. Interval cancer: cancer presenting between screens; ~25% of screen-detected rate; often higher grade Programme aim: detect cancer early enough to improve survival and reduce need for mastectomy Opt-out: women may decline; informed choice supported with balanced information on benefits and harms Source: NHS Breast Screening Programme annual review and PHE quality assurance data FIG 05 Atlas — imaging modalities in breast screening Standard 2D CC + MLO views; routine NHSBSP standard 2D Digital mammo Full-field digital; better for dense breasts FFDM 3D Tomo Tomosynthesis; reduces recall, improves detection DBT Ultrasound Adjunct; dense breasts, palpable abnormality USS Breast MRI High-risk; BRCA1/2, annual from age 30 MRI CEM Contrast-enhanced; emerging for high-risk CEM FIG 06 Key statistics — NHSBSP 2.7M women invited per year [1] 71% uptake rate screening attendance [1] 8,500+ cancers detected annually [2] 1,300 lives saved per year (est.) [3] FIG 07 References 1. NHS Breast Screening Programme. Annual Review 2023. NHS England. 2. Public Health England. Breast screening: data tables and reports. PHE Publications 2023. 3. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778–1786. 4. NICE NG12. Suspected cancer: recognition and referral. National Institute for Health and Care Excellence 2023. 5. PHE Screening Quality Assurance Service. Breast screening: quality assurance standards. SQAS 2022. All information for educational purposes only. Clinical decisions should be based on individual assessment and current NHSBSP guidance. Content reviewed against NHSBSP, NICE NG12 and PHE quality assurance standards. Breastory Encyclopedia of Breast Health. For professional and educational reference only. Please review the latest clinical guidelines for current screening eligibility and management protocols. Clinically authored by Dr Fiona Tsang-Wright , FRCS (Gen Surg) GMC 4549831 · ORCID 0000-0003-4801-026X
Visual Reference · Breast cancer screening
Open full size ↗
Definition
Breast cancer screening is the routine use of imaging — usually mammography — to look for early breast cancer in women who have no symptoms, with the aim of finding cancer before a lump can be felt and when treatment outcomes are best. In the UK, screening is offered through the NHS Breast Screening Programme to women aged 50 to 71, and through private screening services to a wider age range and on a more flexible schedule.

Common questions The questions patients ask first

At what age does NHS breast cancer screening start?
The NHS Breast Screening Programme invites women from age 50 to 711, with the first invitation arriving between the 50th and 53rd birthday. Some areas are extending to age 47 as part of an ongoing programme expansion.
Should I have a private mammogram before age 50?
For women at average risk, the evidence for screening before 50 is weaker than from 50 onwards2. For women with significant family history, an earlier and more intensive pathway is usually appropriate — but that should be set up through a familial-risk clinic3, not by ad hoc private mammograms. Private mammography from 40 for women with concerns or a less-strong family history is reasonable as an adjunct, with realistic expectations of the benefit.
How often should I have a mammogram?
NHS programme: every 3 years from 501. Private (average risk): often offered annually, though every 2 years is also reasonable. High-risk pathway: annual, sometimes with additional MRI34.
Is breast self-examination part of screening?
Self-examination as a structured monthly checklist is no longer formally recommended. The current advice is breast awareness — knowing what is normal for you and noticing changes — rather than a fixed examination routine. If you notice a change, that is the trigger to see a doctor, not the trigger to do a more careful self-exam.
Can men have breast cancer screening?
Routine population screening is not offered to men because male breast cancer is rare. Men with a known BRCA2 mutation or a strong family history may be enrolled in a specialist surveillance pathway through a genetics service3.

Breast cancer screening is the routine use of imaging — usually mammography — to look for early breast cancer in women who have no symptoms, with the aim of finding cancer before a lump can be felt and when treatment outcomes are best. In the UK, screening is offered through the NHS Breast Screening Programme to women from age 50 up to the 71st birthday, and through private screening services to a wider age range and on a more flexible schedule.

Screening is for people without symptoms. Diagnostic assessment is for people who have a symptom (a lump, a change in the breast, a discharge). The test used (mammogram, ultrasound, or MRI) and the right age to start depend on personal risk: average-risk women are screened from 50 on the NHS programme; women with significant family history or a known gene mutation are screened earlier and more intensively. If you have a symptom, do not wait for screening — see breast lump for what to do.

Orientation Why you might be reading about this

You may be wondering when to start having mammograms, whether to pay privately for a screening mammogram before your NHS invitation arrives, or whether your family history changes when screening should begin. This page explains what screening covers, what it doesn’t cover, and how the NHS programme and private screening sit alongside each other. It is not a replacement for a personalised risk assessment.

Related terms: Mammogram · Breast MRI · Breast ultrasound · Tomosynthesis · Family history · Risk assessment

Aim What screening tries to do

Breast cancer screening looks for cancer at a stage when it is small, has not spread, and is most easily treated6. It does this by imaging the breast at intervals over many years, so that any new abnormality stands out from a baseline of “normal for this person.” When screening works, it finds cancers that would otherwise have grown and presented as a lump months or years later, and the treatment is usually less extensive.

Screening does not prevent cancer — it finds cancer earlier than it would otherwise be found. The trade-off is that some screening findings turn out, after biopsy, not to be cancer (false positives), and a small fraction of cancers detected by screening would never have caused a problem in the patient’s lifetime if left alone (overdiagnosis)2. The benefit-to-harm balance is favourable in the age group where breast cancer is common26; outside that age group it is more nuanced.

NHS programme The NHS Breast Screening Programme

The standard offer in the UK:

  • From age 50 up to the 71st birthday, women are invited every 3 years for a mammogram1. The first invitation arrives sometime between the 50th and 53rd birthday1 — invitations come from the local screening unit, not the GP.
  • The mammogram is done at a screening centre or a mobile unit, and reads are quality-controlled by two independent radiologists.
  • Women aged 71 and over are not automatically invited but can self-refer to continue screening.
  • Women aged 47 to 49 and 71 to 73 may be invited in areas participating in the AgeX randomised trial — a research study (not routine programme expansion); results are expected in the mid-2020s.

The programme is comprehensive and free. Detailed information is in the official NHS material (linked at the foot of this page).

Beyond NHS When NHS screening is not enough — earlier or more intensive

For some women, the standard “from age 50 every 3 years” screening is too late, too infrequent, or both. The NHS provides additional screening pathways for these groups:

  • Strong family history — typically defined by NICE CG164 criteria3 (multiple close relatives affected, especially under 50; bilateral or ovarian cancer in the family). Women in the moderate-risk category are offered annual mammography from age 40 (continuing through the NHS programme from 50); in the high-risk category, annual breast MRI from age 30 for BRCA1/BRCA2 carriers (from age 20 for TP53), with annual mammography added from age 40 — MRI is not offered for high-risk-by-family-history alone below the genetic threshold.
  • Known gene mutation (BRCA1 / BRCA2, PALB2, others) — annual breast MRI from age 30{nd}49 for BRCA1/BRCA2 carriers, with annual mammography added from age 40, often through a regional genetics centre.
  • Previous chest radiotherapy (e.g. childhood lymphoma treatment) — earlier and more intensive screening from 8 years after the radiotherapy3 or from age 25, whichever is later.

If you think you may fall into any of these groups, ask your GP for a referral to a familial-risk clinic. See the family history and risk assessment entries for what’s involved.

Private route Private screening

Private screening offers more flexibility:

  • Earlier first mammogram — typically from age 40 (some clinics offer earlier in specific circumstances, with the radiologist’s input on whether that is appropriate).
  • Annual rather than every 3 years if preferred1.
  • Combined modality — mammogram plus ultrasound, or mammogram plus MRI in higher-risk patients.
  • Same-day or next-day reporting rather than the standard NHS turnaround.

Private screening does not replace the NHS programme1 — many patients use both, particularly during their 40s before the NHS programme starts.

The cost depends on the imaging used. A standard private screening mammogram is typically a few hundred pounds; mammogram-plus-ultrasound is more; an MRI screening (used in higher-risk patients) is more again. See fees and insurance for the practice’s specific pricing.

Comparison Mammogram, ultrasound, MRI — what’s the difference?

For screening purposes:

  • Mammogram — the gold standard for breast cancer screening in average-risk women. Catches most cancers, including very small ones detectable only by microcalcifications. Less effective in dense breast tissue.
  • Ultrasound — useful as an adjunct to mammography in dense breasts, to characterise findings, or in younger women where breast tissue density makes mammography less reliable. Not normally used alone for screening.
  • Breast MRI — most sensitive imaging available. Reserved for high-risk women (gene mutations, very strong family history, prior chest radiotherapy) where the additional sensitivity outweighs the higher false-positive rate.
  • Tomosynthesis (3D mammography) — a modern variant of mammography that improves cancer detection particularly in dense breasts5. Increasingly the default in private screening; rolling out gradually on the NHS programme.

Limitations What screening does not do

  • It does not detect every cancer. Some cancers, particularly fast-growing ones, can develop between screening rounds. If a new lump or change appears between screening mammograms, it should be assessed promptly — do not wait for the next routine appointment.
  • It is not a substitute for being aware of your own breasts. Knowing what is normal for you means you notice changes between screens. The NHS phrase “Be Breast Aware” is the operating principle — there is no fixed checklist or timing, just regular awareness.
  • It is not appropriate for symptoms. A lump or other change is a reason to see a doctor for assessment, not to wait for a screening appointment. The right pathway is a one-stop breast clinic appointment via a GP referral or self-referral.

At consultation What to discuss with your GP or surgeon

  • Should I be in a familial-risk pathway rather than standard screening, given my family history?
  • Is private screening worth it before the NHS programme starts, given my personal risk profile?
  • What modality is right for me — mammogram alone, or mammogram with ultrasound, or MRI?
  • What does an abnormal screen mean — what happens next if something is flagged on a mammogram?

Resources Further reading

Sources & guidance

Every figure on this page is anchored to a published source. Tap a number in the text or below to jump to the reference.

  1. programme Public Health England / NHS England. NHS Breast Screening Programme. London: gov.uk. 2024 https://www.gov.uk/guidance/breast-screening-programme-overview Cited for: NHS breast screening invitation age range (50-71), three-year interval, organisation of double-reading mammography.
  2. review Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. British Journal of Cancer. 2013 ;108(11):2205-2240 doi:10.1038/bjc.2013.177 Cited for: UK independent review of NHS Breast Screening Programme — mortality reduction and overdiagnosis estimates.
  3. guidance National Institute for Health and Care Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history. NICE clinical guideline CG164. London: NICE. 2019 https://www.nice.org.uk/guidance/cg164 Cited for: Risk thresholds (population/moderate/high), surveillance schedules, genetic testing criteria, chemoprevention guidance.
  4. guideline Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians. 2007 ;57(2):75-89 doi:10.3322/canjclin.57.2.75 Cited for: Threshold for MRI surveillance: lifetime breast cancer risk >=20-30%.
  5. cohort Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013 ;267(1):47-56 doi:10.1148/radiol.12121373 Cited for: Tomosynthesis improves cancer detection over digital mammography alone in screening, particularly in dense breasts.
  6. cohort Tabár L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011 ;260(3):658-663 doi:10.1148/radiol.11110469 Cited for: Long-term mammographic screening reduces breast cancer mortality — landmark Swedish two-county trial.